Braak stage 1, 100% of pigmented neurons left
parkinsonconnecting

Gene record

PDGFRA

platelet derived growth factor receptor alpha

translation score 0.57, read 2026-10-17; 2 sealed predictions, 0 held; 2 receipts.

Six readers

readerfoundscore
genetics
Open Targets		no genetic evidence; overall 0.38 from other evidence0.00
cell type
Human Protein Atlas		group enriched, including oligodendrocyte progenitor cells; strongest in peritubular myoid cells0.75
chemistry
Open Targets		compounds already reach it: su-014813, famitinib, tak-593 +301.00
trials
ClinicalTrials.gov		no Parkinson's trials on record: an open field1.00
literature
PubMed		3 Parkinson's papers of 3,8080.82
pathways
Reactome		13 pathways; mostly growth signalling0.60
proposal for PDGFRA, translation score 0.57

Knock down and overexpress PDGFRA in oligodendrocytes; measure phospho-ERK and phospho-AKT response to GDNF and α-synuclein uptake and myelin basic protein output under oxidative stress.

Cell type
oligodendrocytes
Direction
Both arms: public data does not say which way helps; existing compounds already reach the inhibition arm.
Molecular readout
phospho-ERK and phospho-AKT response to GDNF
Functional readout
α-synuclein uptake and myelin basic protein output under oxidative stress
Rule-out
If neither arm moves phospho-ERK by 20% or more against non-targeting and empty-vector controls, across three independent differentiations, the hypothesis is wrong.
Lab request
CRISPRi knockdown and lentiviral overexpression of PDGFRA in iPSC-derived oligodendrocytes; n = 3 differentiations; readouts: phospho-ERK and phospho-AKT response to GDNF; α-synuclein uptake and myelin basic protein output under oxidative stress. Controls: non-targeting guide, empty vector. About 8 to 10 weeks, most of it differentiation.

Sealed predictions

  1. PDGFRA in oligodendrocytes, braak-0.27 (p 0.487) → -0.17 (p 0.665)receipt 0707
  2. PDGFRA in dopamine neurons, braak+0.44 (p 0.237) → +0.37 (p 0.329)receipt 0708

Swarm cases

receipt 0708: PDGFRA in dopamine neurons, braak

power
full sample +0.36 (p 0.145, n 18), 95% CI -0.13 to +0.71. the interval is wide: not enough donors to tell.
confounder
adjusted for sex: +0.28 (p 0.258, n 18). does not hold up.
composition
dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.40 (p 0.097, n 18). could be the mix.
skeptic
leave-one-out range +0.26 to +0.44, sign flips 0; without severely affected donors +0.36 (p 0.145, n 18). fragile.
cell type
no other cell group does better.
axis
no measure beats "tracks Braak Lewy-body stage" for PDGFRA in dopamine neurons.

case closed: nothing better to follow up.

receipt 0707: PDGFRA in oligodendrocytes, braak

power
full sample -0.27 (p 0.277, n 18), 95% CI -0.65 to +0.22. the interval is wide: not enough donors to tell.
confounder
adjusted for sex: -0.29 (p 0.235, n 18). does not hold up.
composition
oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.37 (p 0.135, n 18). could be the mix.
skeptic
leave-one-out range -0.38 to -0.16, sign flips 0; without severely affected donors -0.27 (p 0.277, n 18). fragile.
cell type
no other cell group does better.
axis
no measure beats "tracks Braak Lewy-body stage" for PDGFRA in oligodendrocytes.

case closed: nothing better to follow up.

Receipts

loading the receipts